| Name | Title | Contact Details |
|---|
Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well certain genetic diseases such as polycystic kidney disease.
ServRx is a leading national workers` compensation prescription drug claims processing company. With a strong backbone of proprietary IT and decades of experience in the workers` compensation space, ServRx serves a rapidly growing share of community and independent pharmacies. Across America, each pharmacy client is as unique as the injured workers they treat. ServRx prides itself on creating customized solutions to meet the needs of our diverse client-base. Rural mom-and-pop pharmacies, regional chains, specialty pharmacies, and large pharmacy management firms alike have turned to ServRx to handle the unique workflow and cash-flow challenges posed by workers` compensation. A winning mix of experience, technology, and economies of scale allows ServRx to promise its clients superior handling of their workers` compensation claims. Whether they process one pharmacy claim per week, or hundreds per day, ServRx clients have something in common: peace of mind and increased profitability.
Pharmacyvillage.com is a Norman, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hospice Austin serves all of Travis, Williamson, Bastrop, Hays and Caldwell counties.
Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end stage kidney disease (ESKD). Pathalys` initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys is headquartered in Research Triangle Park, North Carolina.